Physician profile
Reed Michael Thomas
NPI 1427408038
$7,605.76
in general payments reported to CMS, 2019-2025
45 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $967 · 2021: $1,498 · 2022: $1,358 · 2023: $1,027 · 2024: $1,437 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,549.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,077.80 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $935.44 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $748.07 | 2020-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $706.99 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $487.83 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $469.79 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $366.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $359.30 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $334.52 | 2019-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Takeda Pharmaceuticals U.S.A., INC. | $316.80 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.66 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.17 | 2020-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $148.84 | 2021 | |
| Amarin Pharma, INC. | $128.76 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $128.61 | 2020-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reed Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.